Fiche société
Herantis Pharma Plc.
Traitements, essais et publications liés.
Traitements3programmes
Essais2liés
Publications2liées
SourceDBlocale
Traitements
3| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| HER-096This study evaluates the safety and tolerability of HER-096 in healthy volunteer subjects by comparing the effects of active study treatment HER-096 to placebo (0.9% physiological saline). In addition, the pharmacokinetic profile of HER-096 in humans will be investigated. The investigational medicinal products will be administered as a single dose by subcutaneous injection. | Parkinson | Phase 1 | À vérifier | Finland | À vérifier |
| HER-096This study evaluates the safety and tolerability of HER-096 in healthy volunteer subjects by comparing the effects of active study treatment HER-096 to placebo (0.9% physiological saline). In addition, the pharmacokinetic profile of HER-096 in humans will be investigated. The investigational medicinal products will be administered as a single dose by subcutaneous injection. | Parkinson | Phase 1 | À vérifier | Finland | À vérifier |
| HER-096This study evaluates the safety and tolerability of HER-096 in healthy volunteer subjects by comparing the effects of active study treatment HER-096 to placebo (0.9% physiological saline). In addition, the pharmacokinetic profile of HER-096 in humans will be investigated. The investigational medicinal products will be administered as a single dose by subcutaneous injection. | Parkinson | Phase 1 | À vérifier | Finland | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| HER-096 | Parkinson | Phase 1 | NCT06659562 | Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease | COMPLETED |
| HER-096 | Parkinson | Phase 1 | NCT05915247 | Single Ascending Doses of HER-096 in Healthy Subjects | COMPLETED |
Publications
2| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| HER-096 | Brain-penetrating neurotrophic factor mimetics: HER-096 as a disease-modifying therapy for Parkinson's disease. | Neural regeneration research | ||
| HER-096 | Cerebral dopamine neurotrophic factor and its functional fragments induce calcium signal through sigma-1 receptor and protect neurons against glutamate-induced excitotoxicity. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |